Navigation

Health fund seeks compensation from pill maker

The pill is a popular means of birth control Keystone

Complications attributed to the use of the Yasmin contraceptive pill have prompted a Swiss health insurance company to demand hundreds of thousands of francs from the German pharma giant, Bayer, to pay for a client’s treatment.

This content was published on January 9, 2013 - 10:14
swissinfo.ch and agencies

The claim arose after a young woman suffered a pulmonary embolism after taking the pill, leaving her severely handicapped. Her family has already launched a legal case against Bayer on their own account. Their lawyer told Swiss television on Tuesday that the CSS insurance company had now made a so-called “third party intervention” in her support.

He said CSS had so far paid out SFr600,000 ($650,000) for her treatment, and more than SFr900,000 in another case.

“It is not right that the community should pay while the Bayer company makes a profit,” he said.

Until 2010 Yasmin, a “fourth generation” pill, was the best-selling hormonal contraceptive in Switzerland. Fourth generation pills were popular because women using them did not put on as much weight as with earlier pills.

In 2009 Swissmedic, the agency that supervises therapeutical products, found that it did present a higher risk of thrombosis than second generation pills, but was safer than pills of the third generation. But it stressed that women should only use hormonal methods after consulting their doctor.

Just before Swissmedic announced its findings, a woman died of a pulmonary embolism ten months after she started taking Bayer’s Yaz contraceptive, the lower dose version of Yasmin. 

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.